Central England Haemato-oncology and oncology Research Biobank (CEHRB)
https://bwc.nhs.uk/central-england-haemato-oncology-and-oncology-research-bioba
The Central England Haemato-Oncology and oncology Research BioBank (CEHRB) predominantly stores excess material from haemato-oncology and oncology samples referred for diagnostic testing and disease monitoring at the West Midlands Regional Genetics Laboratory (WMRGL). Haemato-oncology samples are stored at presentation and throughout the disease course, including at remission and relapse. In addition CEHRB stores haemato-oncology and oncology samples which are specifically taken for the biobank, usually in response to a specific project. CEHRB is housed within the WMRGL which is accredited by United Kingdom Accreditation Services to ISO15189:2012. The WMRGL serves a population of about 6 million and is the largest UK NHS genetics lab. Due to the large patient population CEHRB is able to collate sufficient research material from all classifications of neoplastic haematological disorders including those that are rare.
Services
- Access to the full pathology archive
- Cell culture
- Nucleic acid extraction
Existing samples:
- Leukemia, disease (disorder)
Contact Information
- Email:
- bwc.cehrb_@nhs.net
- Telephone:
- 0121 335 8036
- Address:
-
West Midlands Regional Genetics Laboratory
Birmingham Women's & Children NHS Foundation Trust
Mindelsohn Way
Edgbaston
Birmingham
West Midlands
B15 2TG
England
Last Updated: 07/24/2019
Annual Statistics
Year | Access Requests Received | Access Requests Approved | ||||
---|---|---|---|---|---|---|
Internal | External | Commercial | Internal | External | Commercial | |
2015 | N/A | N/A | N/A | N/A | N/A | N/A |
2016 | N/A | N/A | N/A | N/A | N/A | N/A |
2017 | N/A | N/A | N/A | N/A | N/A | N/A |
2018 | N/A | N/A | N/A | N/A | N/A | N/A |
2019 | N/A | N/A | N/A | N/A | N/A | N/A |
2020 | N/A | N/A | N/A | N/A | N/A | N/A |
2021 | N/A | N/A | N/A | N/A | N/A | N/A |
2022 | N/A | N/A | N/A | N/A | N/A | N/A |
2023 | N/A | N/A | N/A | N/A | N/A | N/A |
2024 | N/A | N/A | N/A | N/A | N/A | N/A |